Abstract
The Department of Medicine played a seminal role in managing the crisis from the COVID-19 pandemic at Saint Barnabas Hospital (SBH) Health System that started in mid-March and reached its zenith in New York City in mid-late April 2020. Internal medicine, under normal circumstances, deals with a wide range of diseases and disproportionate impact from social determinants of health. The COVID-19 crisis completely upended the very systematic process of caring for this broad range of patients. Within a relatively short period of time – days to weeks – it required an almost complete reconfiguration of staffing, roles, and methods of communication to allow effective care for a large number of very sick patients. This chapter documents how Internal Medicine implemented those changes rapidly and the dynamic modifications that were made throughout the initial surge as the crisis took hold, to ultimately work efficiently and effectively in the fight against COVID-19. Specifically, the number of beds capable of caring for COVID-19 patients dramatically increased and multiple administrative spaces were transformed into clinical wards. The number of hospitalists progressively and rapidly increased leading to two COVID-19 services run by primary care physicians and additional services led by oncology, cardiology, and gastroenterology specialists, alongside a multidisciplinary COVID-19 Treatment Committee that made institutional recommendations about treatments. As many practices were standardized throughout the institution optimizing patient care and likely preventing many patients from requiring mechanical ventilation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Beigel JH, Tomashek KM, Dodd L, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19. N Engl J Med. 2020;383(19):1813–26. https://doi.org/10.1056/NEJMoa2007764.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–78. https://doi.org/10.1016/S0140-6736(20)31022-9.
Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324(13):1307–16. https://doi.org/10.1001/jama.2020.17021.
Kalil AC. Treating COVID-19—off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA. 2020;323(19):1897–8. https://doi.org/10.1001/jama.2020.4742.
Acknowledgments
Susan Singh, MPH Director of Infection Control
Victoria Bengualid, MD, Director of Graduate Medical Education
Anita Soni, MD, Director of Hospitalist Service.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Telzak, E.E., Berger, J. (2022). Internal Medicine, Infection Control, and Occupational Health Services. In: Shabsigh, R. (eds) Health Crisis Management in Acute Care Hospitals . Springer, Cham. https://doi.org/10.1007/978-3-030-95806-0_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-95806-0_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-95805-3
Online ISBN: 978-3-030-95806-0
eBook Packages: MedicineMedicine (R0)